Pharmaceutical Technology
FEBRUARY 27, 2023
Hydrocortisone is under clinical development by Antares Pharma and currently in Phase I for Adrenal Insufficiency. According to GlobalData, Phase I drugs for Adrenal Insufficiency have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is administered by parenteral route.
Pharmaceutical Technology
SEPTEMBER 20, 2022
The information contained within the download document is intended for pharmaceutical manufacturers, wholesalers, retailers and distributors, pharmaceutical executives, medical representatives, business development managers, retail salesmen, sales managers, pharmacy executives, and any other individual involved in pharmaceutical marketing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JULY 31, 2023
CS Pharmaceuticals (CSP) has acquired AxeroVision, a company developing novel therapies for the treatment of dry eye disease (DED) and other ophthalmic inflammatory diseases that address the underlying inflammatory processes.
Roots Analysis
AUGUST 8, 2023
The phospholipid bilayers continuously surround the dispersing aqueous media and create a vesicular system in response to mechanical shaking or heating. The hydrophobic portion contains two fatty acid chains with 10-24 carbon atoms, while the hydrophilic part primarily consists of phosphoric acid linked to a water-soluble molecule.
Drug Discovery World
AUGUST 9, 2023
Darren Mercer, Chief Executive of CSP, said: “We are thrilled to acquire AxeroVision, and in particular the pipeline product AXR-270 which contains a novel selective glucocorticoid receptor agonist formulated in a cutting-edge drug delivery system that overcomes the issues of poor compliance and inefficient delivery of conventional eye drops.”
Drug Discovery World
OCTOBER 19, 2022
Ashley Rein , Global Market Manager for Topical Drug Delivery at Lubrizol Life Science Health (LLS Health), explains how by using mucoadhesive drug delivery, developers can bring novel drugs to market and maximise the efficacy of pre-existing APIs. . Consider drug delivery systems early on .
Roots Analysis
FEBRUARY 18, 2022
Myeloid cells represent a group of cells containing granulocytes, monocytes, macrophages, mast cells and dendritic cells, which play a key role in innate immunity. The key focus of these studies is on the development of anti-tumor therapeutics. These cells are found in abundance in the tumor microenvironment and inflamed areas.
Expert insights. Personalized for you.
100 
Let's personalize your content